News BioRestorative Therapies, Inc.

Stocks

BRTX

US0906557055

Biotechnology & Medical Research

Market Closed - Nasdaq 16:30:00 2026-10-30 EDT			5-day change	1st Jan Change
1.400 ^USD	-11.37%		-13.56%	-94.04%

10-09	BioRestorative Therapies, Inc. Announces Board and Committee Changes	CI
10-06	Maxim Downgrades BioRestorative Therapies to Hold From Buy	MT

All News

Mentions Relevance

10-09	BioRestorative Therapies, Inc. Announces Board and Committee Changes	CI
10-06	Maxim Downgrades BioRestorative Therapies to Hold From Buy	MT
09-02	BioRestorative Therapies Announces Reverse Stock Split	GL
09-02	BioRestorative Therapies, Inc. Announces CEO Changes, Effective August 26, 2026	CI
09-02	BioRestorative Therapies, Inc. Announces CFO Changes, Effective August 27, 2026	CI
09-02	BioRestorative Therapies, Inc. Announces Executive Changes, Effective August 27, 2026	CI
08-14	BioRestorative Therapies, Inc. Suspends All Orders And Shipments Of Biocosmeceutical Product Lines	CI
07-16	BioRestorative Therapies, Inc. Announces CEO Changes, Effective July 13, 2026	CI
07-16	BioRestorative Therapies, Inc. Announces CFO Changes, Effective July 13, 2026	CI
07-16	Biorestorative Therapies, Inc. Announces Board and Management Changes	CI
06-25	BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform	AQ
06-25	BioRestorative Therapies Completes Manufacturing for BRTX-100 Phase 2 Clinical Trial	CI
06-18	BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth	AQ
06-15	BioRestorative Therapies, Inc.'s Equity Buyback announced on August 12, 2025, has expired.	CI
06-12	BioRestorative Therapies, Inc. Announces Board and Committee Changes	CI
06-12	BioRestorative Therapies, Inc. Enters Into $1,000,000 Revolving Loan Agreement With Bowery Group LLC	CI
05-27	Kaos Capital acquires 4.9% stake in BioRestorative Therapies	RE
05-27	Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)	AQ
05-27	Kaos Capital Engages with BioRestorative Therapies	CI
05-26	BioRestorative Completes Dosing in Phase 2 Trial of BRTX-100 to Treat Chronic Lumbar Disc Disease; Shares Rise	MT
05-26	Biorestorative Therapies says topline phase 2 data for BRTX-100 expected in Q2 2027	RE
05-26	BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data	AQ
05-26	BioRestorative Therapies, Inc. Completes Phase 2 Dosing Of BRTX-100 And Advances Lead Regenerative Spine Program Toward 2027 Topline Data	CI
05-14	9,046,242 Common Stock of BioRestorative Therapies, Inc. are subject to a Lock-Up Agreement Ending on 15-MAY-2026.	CI
05-14	Certain Series B Preferred Stock of BioRestorative Therapies, Inc. are subject to a Lock-Up Agreement Ending on 15-MAY-2026.	CI